properties of B12019 and Neulasta at the clinical dose of 6 mg. In the second trial, Cinfa Biotech administered a reduced, 3 mg dose to 96 volunteers to generate PD and immunogenicity data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback